Pozelimab may offer an alternative therapeutic option for patients suffering from PNH and aHUS, as our PK/PD results suggest that it may require less frequent dosing, normalize serum C5 levels and be efficacious in patients that carry rare C5 variants. The gene discussed is C5; the disease is paroxysmal nocturnal hemoglobinuria.